Verastem (VSTM) Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary

Commercial performance and market uptake

• Achieved over 50% sales growth from Q2 to Q4, beating analyst consensus for three consecutive quarters.

• Drug adoption is broad, with strong uptake in both major academic centers and large community practices.

• Average patient duration on therapy is 18 months, supporting a recurring revenue model.

• Reimbursement is robust for both on-label and off-label use, including KRAS wild type cases.

• A new promotional campaign is launching to position the therapy as the preferred post-frontline option.

Clinical development and trial updates

• Confirmatory trial (RAMP 301) completed accrual, with a final readout expected around mid-next year.

• Trial size increased from 270 to 300 patients to maintain statistical power, with positive interim feedback.

• Japanese bridging study confirmed efficacy across all patient types, supporting conditional approval in Japan.

• RAMP 205 in pancreatic cancer showed an 83% response rate with full-dose chemo, with expanded cohort data due mid-year.

• G12D inhibitor (VS-7375) demonstrated 58% response in pancreatic and 69% in lung cancer, with U.S. trials showing improved tolerability.

Strategic outlook and future plans

• Awaiting potential NCCN guideline inclusion, which could further boost growth.

• RAMP 301 could expand the addressable U.S. market to 6,000–10,000 patients if wild type is included.

• U.S. phase I study of VS-7375 is progressing, with single-agent and combination arms in multiple cancers.

• Plans to pursue both single-agent and combination strategies in front-line lung and pancreatic cancers.

• Company-sponsored events will provide key data updates on pipeline progress throughout the year.